par Lisa Chamoff
, Contributing Reporter | June 17, 2019
From the June 2019 issue of HealthCare Business News magazine
Segami Corporation CERQuant
“We can isolate different areas of the brain, which gives us a lot more precise information to be able to quantify those areas for perfusion,” said John Zurita, director of global business development for Segami Corporation.
In addition, the company has a new product that can fuse a SPECT study with CT or MR and quantify hyperperfusion or hypoperfusion.
“We increase the specificity and sensitivity, and are better able to analyze the area for hyper or hypoperfusion,” Zurita said.
The company also recently released SISCOM, or Subtraction Ictal SPECT Co-registered to MRI, a neuroimaging application to evaluate epilepsy. It performs a comparison of Ictal and Inter-ictal SPECT images, performs automatic co-registration of SPECT images with MRI, displays delta results of registered Images and displays precise anatomic location of seizure focus prior to surgery.
“By co-registering with MRI, we increase the specificity ,” Zurita said.
In 2016, Cubresa introduced its NuPET, a preclinical PET insert that fits inside an MR scanner for imaging mice and other small animals.
The company is planning to come out with a larger version of the NuPET for larger animals. It also recently entered into a joint venture with the Gaoxin Group, a Chinese investment group, to develop the same technology for clinical brain imaging, said James Schellenberg, founder and chief executive officer of Cubresa.
“The closer you get to the head, the better the images are,” Schellenberg said. “The BrainPET insert is the combination of a head coil with a PET ring wrapped around it. The big advantage of this product for clinical imaging is that the spatial resolution is improved. BrainPET will provide the best resolution for brain imaging, and will be of interest to research institutions and clinical centers. In addition, the sensitivity will be superior, so less dose will be required.”